Pre-earnings options volume in FibroGen (FGEN) is normal with calls leading puts 11:1. Implied volatility suggests the market is anticipating a move near 18.1%, or 0c, after results are released. Median move over the past eight quarters is 14.0%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- Options Volatility and Implied Earnings Moves Today, March 17, 2025
- Is FGEN a Buy, Before Earnings?
- FibroGen’s Strategic Sale and Pipeline Focus Justify Buy Rating Amid Financial Strength
- FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright
- M&A News: AstraZeneca Expands China Footprint With FibroGen Deal